Case Summary (UDK No. 16838)
Factual Background
Petitioner sought a writ of mandamus to compel respondents to observe Food and Drug Administration rules on acquisition, procurement and use of drugs and vaccines, and to order the DOH FDA to issue a cease-and-desist order against procurement and use of the Sinovac COVID-19 vaccine. Petitioner alleged doubts about the Sinovac vaccine’s efficacy and the absence of Philippine clinical trials establishing its effectiveness, and prayed that all COVID-19 vaccines undergo required Philippine trials before emergency or regular use.
Presidential Immunity from Suit
The Court held that President Rodrigo R. Duterte must be dropped as a respondent because an incumbent President cannot be sued during the President’s tenure. The Court relied on its prior rulings including De Lima v. President Duterte, and on constitutional history explaining that presidential immunity during tenure exists irrespective of the nature of the suit or whether the acts alleged are official or personal. The Court reiterated that immunity is intended to prevent distractions from the President’s discharge of executive duties and that accountability of the President is preserved through impeachment, not through ordinary suits.
Legal Standard for Mandamus
The Court applied Rule 65, Section 3 to describe the two situations warranting mandamus: unlawful neglect of a duty specifically enjoined by law and unlawful exclusion from a right or office. The Court emphasized that mandamus compels only ministerial acts, not discretionary ones, citing Philippine Coconut Authority v. Primex Coco Products, Inc. and related authorities. A ministerial duty is one that an officer must perform on prescribed facts without exercising judgment; a discretionary duty requires judgment and cannot be compelled by mandamus.
Absence of a Ministerial Duty to Conduct Local Clinical Trials
Applying the mandamus standard, the Court found that petitioner failed to identify any statutory provision imposing a ministerial duty on respondents to conduct Philippine clinical trials prior to procurement or use of a COVID-19 vaccine. At the time the national government negotiated procurement of Sinovac, no law mandated mandatory Philippine clinical trials for COVID-19 vaccines; indeed, Sec. 12 of R.A. 11494 temporarily waived the Phase IV trial requirement for COVID-19 medication and vaccines for a defined period. The Court concluded that the conduct and timing of vaccine procurement and authorization involved discretionary judgments entrusted to the executive.
Emergency Use Authorization and the Authority of the FDA
The Court explained that Executive Order No. 121 authorized the Director-General of the FDA to issue an Emergency Use Authorization (EUA) for COVID-19 drugs and vaccines and delineated the conditions for an EUA: reasonable belief in potential effectiveness based on the totality of evidence, a favorable balance of benefits over risks, and the absence of adequate approved alternatives. The issuance of an EUA precludes the need for completion of clinical trials in the Philippines. The Court noted that the FDA may consider foreign trial results and that the FDA had granted an EUA to Sinovac on February 22, 2021. In the absence of proof that the EUA was issued unlawfully, the Court declined to order additional trials.
Legislative Grants of Discretion and Procurement Exceptions
The Court observed that R.A. 11494 explicitly authorized the President to exercise necessary and proper powers to implement COVID-19 response interventions, thereby conferring broad discretion to adopt WHO and other international standards. The subsequent enactment of R.A. 11525 (the COVID-19 Vaccination Program Act of 2021) further authorized the DOH and the National Task Force to procure COVID-19 vaccines and ancillary supplies through Negotiated Procurement under Emergency Cases and exempted such procurement from the general public bidding requirement. R.A. 11525 also required that only vaccines with a valid Certificate of Product Registration or an EUA may be procured. Given these statutory grants, the Court held that no legal ground existed to compel clinical trials or public bidding where the vaccine possessed an EUA.
Improper Forum and the Doctrine of Hierarchy of Courts
The Court held that petitioner’s direct resort to the Supreme Court was improper. Challenges to vaccine efficacy are factual matters beyond the Court’s role as trier of facts. Section 21 of B.P. 129 grants original jurisdiction over mandamus to Regional Trial Courts, and the doctrine of hierarchy of courts requires that extraordinary writs normally be sought first in lower courts. The Court reiterated its prior pronouncements in cases such as Gios-Samar Inc. v. Department of Transpo
...continue reading
Case Syllabus (UDK No. 16838)
Parties and Posture
- Pedrito M. Nepomuceno filed a petition for a writ of mandamus against President Rodrigo Duterte, Secretary Francisco Duque, Department of Health, Inter-Agency Task Force on Emerging Infectious Diseases, and Gen. Carlito Galvez Jr. (Ret.).
- The petitioner sought an order compelling respondents to observe Food and Drug Administration (FDA) rules on drug acquisition and procurement and to require local clinical trials prior to the emergency or regular use of COVID-19 vaccines.
- The petition specifically targeted the planned procurement and deployment of the Sinovac COVID-19 vaccine and prayed for a cease-and-desist order against its purchase and use.
- The Court resolved the petition by way of a resolution dismissing the petition and ordering that President Rodrigo Duterte be dropped as a respondent.
Key Facts
- The national government announced plans to procure COVID-19 vaccines produced by Sinovac for distribution and administration in the Philippines.
- Reports and public doubts concerning the efficacy of the Sinovac vaccine prompted the petitioner to seek judicial intervention.
- At the time of the planned procurement, legislation and executive issuances had already provided special procedures for COVID-19 vaccine authorization and procurement.
- The FDA granted an Emergency Use Authorization for the Sinovac vaccine on February 22, 2021, as reported in the administrative records cited by the Court.
Issues
- Whether the sitting President was a proper respondent in the mandamus proceeding.
- Whether the petitioner established a clear legal right and identified a ministerial duty that respondents unlawfully neglected such that a writ of mandamus should issue.
- Whether the Supreme Court should exercise original jurisdiction over the petition in the first instance rather than require filing in the appropriate lower court.
Petitioner's Claims
- The petitioner asserted that respondents unlawfully neglected their duty to require local clinical trials prior to procurement and use of COVID-19 vaccines.
- The petitioner alleged that procurement procedures and clinical testing requirements under FDA rules and the Universal Health Care Act were being disregarded.
- The petitioner prayed for the issuance of a writ of mandamus compelling respondents to enforce FDA rules and to issue a cease-and-desist order against the Sinovac vaccine.
Applicable Law
- Section 3, Rule 65 of the Revised Rules of Court governed the requirements for the issuance of the writ of mandamus.
- Republic Act No. 11494 (Bayanihan to Heal as One Act and its extensions) authorized the President to exercise powers necessary and proper for COVID-19 response and waived certain trial requirements under speci